Scarica l'app Stockscreener
1.07
3.88%
0.04
Precedente Chiudi:
$1.03
Aprire:
$1.02
Volume 24 ore:
145.52K
Relative Volume:
1.06
Capitalizzazione di mercato:
$23.48M
Reddito:
-
Utile/perdita netta:
$-13.76M
Rapporto P/E:
-1.1505
EPS:
-0.93
Flusso di cassa netto:
-
1 W Prestazione:
+9.33%
1M Prestazione:
+8.08%
6M Prestazione:
-14.40%
1 anno Prestazione:
-19.55%
Intervallo 1D:
$1.02
$1.09
Intervallo di 1 settimana:
$0.93
$1.09
Portata 52W:
$0.512
$1.50
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Nome
Neurosense Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.07 | 23.48M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks
NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - Quantisnow
Regulatory T-cells (Tregs) Market to Observe Significant Growth by 2034 Owing to the Development in 12+ Indications with Severe and Refractory Patients as the Treatment Addressable Population | DelveInsight - PR Newswire
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan
Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks
Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire
Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com
NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World
NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire
NeuroSense Advances PrimeC Commercialization in Canada - TipRanks
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com
Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan
The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury
NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks
NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World
NeuroSense regains Nasdaq compliance with equity boost - Investing.com
NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria
NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com
Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail
Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World
NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World
Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):